Doxorubicin Inhibits Phosphatidylserine Decarboxylase and Modifies Mitochondrial Membrane Composition in HeLa Cells.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
15 Feb 2020
Historique:
received: 06 01 2020
revised: 11 02 2020
accepted: 13 02 2020
entrez: 21 2 2020
pubmed: 23 2 2020
medline: 24 11 2020
Statut: epublish

Résumé

Doxorubicin (DXR) is a drug widely used in chemotherapy. Its mode of action is based on its intercalation properties, involving the inhibition of topoisomerase II. However, few studies have reported the mitochondrial effects of DXR while investigating cardiac toxicity induced by the treatment, mostly in pediatric cases. Here, we demonstrate that DXR alters the mitochondrial membrane composition associated with bioenergetic impairment and cell death in human cancer cells. The remodeling of the mitochondrial membrane was explained by phosphatidylserine decarboxylase (PSD) inhibition by DXR. PSD catalyzes phosphatidylethanolamine (PE) synthesis from phosphatidylserine (PS), and DXR altered the PS/PE ratio in the mitochondrial membrane. Moreover, we observed that DXR localized to the mitochondrial compartment and drug uptake was rapid. Evaluation of other topoisomerase II inhibitors did not show any impact on the mitochondrial membrane composition, indicating that the DXR effect was specific. Therefore, our findings revealed a side molecular target for DXR and PSD, potentially involved in DXR anti-cancer properties and the associated toxicity.

Identifiants

pubmed: 32075281
pii: ijms21041317
doi: 10.3390/ijms21041317
pmc: PMC7072979
pii:
doi:

Substances chimiques

Phosphatidylethanolamines 0
Phosphatidylserines 0
phosphatidylethanolamine 39382-08-6
Doxorubicin 80168379AG
Carboxy-Lyases EC 4.1.1.-
phosphatidylserine decarboxylase EC 4.1.1.65

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Mol Cancer Ther. 2016 Nov;15(11):2640-2652
pubmed: 27466354
Biochem Pharmacol. 1999 Mar 1;57(5):481-9
pubmed: 9952311
Mol Metab. 2019 Sep;27:33-46
pubmed: 31285171
Biochem Pharmacol. 1976 May 15;25(10):1227-31
pubmed: 945741
Methods Enzymol. 1996;264:484-509
pubmed: 8965721
Cancer Res. 1976 Sep;36(9 pt.1):3246-54
pubmed: 184946
Biochim Biophys Acta. 1979 Nov 2;557(2):306-19
pubmed: 583025
J Biol Chem. 2013 Feb 8;288(6):4158-73
pubmed: 23250747
J Lipid Res. 1983 Sep;24(9):1243-50
pubmed: 6631248
J Biol Chem. 2005 Dec 2;280(48):40032-40
pubmed: 16192276
Anesthesiology. 2009 Mar;110(3):648-59
pubmed: 19212263
J Biomol Screen. 2007 Aug;12(5):628-34
pubmed: 17478478
J Biol Chem. 1991 Jul 5;266(19):12185-8
pubmed: 2061305
Biochemistry. 1985 Dec 3;24(25):7085-92
pubmed: 4084563
Toxicol Lett. 1985 Feb-Mar;24(2-3):119-24
pubmed: 3983963
J Biol Chem. 1985 Oct 25;260(24):13003-7
pubmed: 4055730
Cancer Cell. 2005 Oct;8(4):311-21
pubmed: 16226706
J Biol Chem. 1983 Jan 10;258(1):339-43
pubmed: 6848505
BMC Cancer. 2006 Oct 03;6:234
pubmed: 17018136
Can J Biochem Physiol. 1959 Aug;37(8):911-7
pubmed: 13671378
Proc Natl Acad Sci U S A. 1989 Dec;86(24):9921-5
pubmed: 2602382
Biochem Pharmacol. 1999 Apr 1;57(7):727-41
pubmed: 10075079
Nature. 2008 Mar 13;452(7184):230-3
pubmed: 18337823
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3136-41
pubmed: 14978272
Cancer Res. 1984 May;44(5):1918-23
pubmed: 6713393
J Am Chem Soc. 2004 Aug 4;126(30):9168-9
pubmed: 15281791
Lipids. 2008 Oct;43(10):951-9
pubmed: 18560917
Int J Biochem Cell Biol. 2009 Dec;41(12):2566-77
pubmed: 19712747
J Biol Chem. 1993 Dec 5;268(34):25985-92
pubmed: 8245031
Breast Cancer Res. 2008;10(1):202
pubmed: 18304378
Biochim Biophys Acta. 1986 Jun 16;887(1):35-41
pubmed: 3518812
Nat Rev Cancer. 2002 Jan;2(1):48-58
pubmed: 11902585
PLoS One. 2016 Jul 19;11(7):e0158376
pubmed: 27434059
J Chromatogr. 1978 Dec 11;166(2):637-40
pubmed: 748365
J Lipid Res. 2008 Jul;49(7):1377-87
pubmed: 18204094
Am J Physiol Regul Integr Comp Physiol. 2010 Apr;298(4):R1075-88
pubmed: 20053966
Nat Chem. 2018 Jul;10(7):787-794
pubmed: 29760413
Ann Neurol. 1989 Jul;26(1):20-33
pubmed: 2549843
Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15066-71
pubmed: 12417746
J Biol Chem. 2015 Apr 24;290(17):10981-93
pubmed: 25759382
Biochim Biophys Acta. 1981 Dec 7;649(2):317-24
pubmed: 7317402
Front Biosci (Landmark Ed). 2009 Jan 01;14:4015-34
pubmed: 19273331

Auteurs

Nadège Bellance (N)

INSERM U1211, Rare Diseases: Genetic and Metabolism, F-33076 Bordeaux, France.
University of Bordeaux, F-33076 Bordeaux, France.

Fabienne Furt (F)

University of Bordeaux, F-33076 Bordeaux, France.
UMR 5200 CNRS, Membrane Biogenesis Laboratory, F-33140 Villenave d'Ornon, France.

Su Melser (S)

University of Bordeaux, F-33076 Bordeaux, France.

Claude Lalou (C)

INSERM U1211, Rare Diseases: Genetic and Metabolism, F-33076 Bordeaux, France.
University of Bordeaux, F-33076 Bordeaux, France.

Didier Thoraval (D)

University of Bordeaux, F-33076 Bordeaux, France.
UMR 5200 CNRS, Membrane Biogenesis Laboratory, F-33140 Villenave d'Ornon, France.

Lilly Maneta-Peyret (L)

University of Bordeaux, F-33076 Bordeaux, France.
UMR 5200 CNRS, Membrane Biogenesis Laboratory, F-33140 Villenave d'Ornon, France.

Didier Lacombe (D)

INSERM U1211, Rare Diseases: Genetic and Metabolism, F-33076 Bordeaux, France.
University of Bordeaux, F-33076 Bordeaux, France.

Patrick Moreau (P)

University of Bordeaux, F-33076 Bordeaux, France.
UMR 5200 CNRS, Membrane Biogenesis Laboratory, F-33140 Villenave d'Ornon, France.

Rodrigue Rossignol (R)

INSERM U1211, Rare Diseases: Genetic and Metabolism, F-33076 Bordeaux, France.
University of Bordeaux, F-33076 Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH